Abstract: A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH(1-44)-NH2 or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.23 to about 1.32 mg of a GHRH molecule such as trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of about 7.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of e.g., trans-3-hexenoyl-GHRH(1-44)-NH2 that are bioequivalent to administration of 2 mg of trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of 1 mg/mL in a subject are also described.

Abstract: A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH(1-44)-NH2 or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.3 to about 1.5 mg of a GHRH molecule such as trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of about 3.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of e.g., trans-3-hexenoyl-GHRH1-44)-NH2 that are bioequivalent to administration of 2 mg of trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of 1 mg/mL in a subject are also described.

Abstract: A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH(1-44)-NH2 or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.3 to about 1.5 mg of a GHRH molecule such as trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of about 3.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of e.g., trans-3-hexenoyl-GHRH(1-44)-NH2 that are bioequivalent to administration of 2 mg of trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of 1 mg/mL in a subject are also described.

Abstract: A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH(1-44)-NH2 or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.3 to about 1.5 mg of a GHRH molecule such as trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of about 3.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of e.g., trans-3-hexenoyl-GHRH(1-44)-NH2 that are bioequivalent to administration of 2 mg of trans-3-hexenoyl-GHRH(1-44)-NH2 at a concentration of 1 mg/mL in a subject are also described.

Abstract: The power actuated toilet seat device provides a pair of leg assemblies positioned on opposites sides of a toilet bowl, an expansion cylinder disposed longitudinally on each hind leg, a receiver/activator disposed downwardly in each expansion cylinder, an expansion lift arm disposed upwardly on each expansion cylinder, a follower disposed perpendicularly inward atop each expansion lift arm, a seat having a front spaced apart from a rear, and two spaced apart sides, a slot disposed laterally within each seat side, each slot in receipt of one of the followers of one of each of the expansion lift arms, a hinge disposed downwardly and at the front of the seat, the hinge selectively affixed forwardly to an existing bowl of an existing toilet, a control means configured to control lifting and pivoting of the seat, the control means in communication with each receiver/activator.

Abstract: Improved methods for determining normal IGF-1 levels in HIV infected subjects, based on a determination of the log of IGF-1 values obtained in blood-derived samples from a population of HIV-infected subjects, are disclosed. Also disclosed are methods of determining whether a given HIV-infected subject exhibits a normal IGF-1 level, based on a comparison of either the IGF-1 value or the log of the IGF-1 value obtained from a blood-derived sample of the subject with a normative IGF-1 range determined using the exponentiation of the log of IGF-1 values or the log of IGF-values obtained in blood-derived samples from a population of age- and gender-matched HIV-infected subjects. Such methods are useful for example to monitor GH stimulation therapy in HIV-infected subjects.